{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:31:47Z","timestamp":1790937107091,"version":"4.1.0"},"reference-count":185,"publisher":"Elsevier","isbn-type":[{"value":"9780443297809","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.pmch.2024.08.001","type":"book-chapter","created":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T18:36:26Z","timestamp":1727375786000},"page":"161-234","source":"Crossref","is-referenced-by-count":2,"title":["Another decade of antimalarial drug discovery: New targets, tools and molecules"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.pmch.2024.08.001_bb0010","series-title":"WHO world malaria report 2022","author":"World Health Organisation","year":"2022"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12936-022-04303-6","article-title":"The economic burden of malaria: a systematic review","volume":"21","author":"Andrade","year":"2022","journal-title":"Malar J"},{"issue":"342","key":"10.1016\/bs.pmch.2024.08.001_bb0020","first-page":"684","article-title":"The forgotten malaria","volume":"2013","author":"Vogel","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0025","series-title":"Advances in parasitology","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-397900-1.00001-3","article-title":"The global public health significance of plasmodium vivax","volume":"vol. 80","author":"Battle","year":"2012"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/CMR.00079-12","article-title":"Human infections and detection of Plasmodium knowlesi","volume":"26","author":"Singh","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0035","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.pt.2008.12.002","article-title":"Malaria vector control: current and future strategies","volume":"25","author":"Takken","year":"2009","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0040","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00436-010-2232-0","article-title":"Malaria vector control: from past to future","volume":"108","author":"Raghavendra","year":"2011","journal-title":"Parasitol Res"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0045","first-page":"1","article-title":"New developments in anti-malarial target candidate and product profiles","volume":"16","author":"Burrows","year":"2017","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0050","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/nature01107","article-title":"A proteomic view of the Plasmodium falciparum life cycle","volume":"419","author":"Florens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0055","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrmicro3519","article-title":"Sexual development in Plasmodium parasites: knowing when it's time to commit","volume":"13","author":"Josling","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0060","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0001-706X(94)90061-2","article-title":"The mode of action and the mechanism of resistance to antimalarial drugs","volume":"56","author":"Foote","year":"1994","journal-title":"Acta Trop"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0065","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","article-title":"Clinical pharmacokinetics and pharmacodynamics of Artemether-Lumefantrine","volume":"37","author":"White","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0070","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad9735","article-title":"Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase","volume":"9","author":"Paquet","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0075","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.pt.2021.04.006","article-title":"Assessing risks of Plasmodium falciparum resistance to select next-generation antimalarials","volume":"37","author":"Duffey","year":"2021","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0080","first-page":"18","article-title":"The past, present and future of anti-malarial medicines","author":"Tse","year":"2019","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0085","doi-asserted-by":"crossref","DOI":"10.7860\/JCDR\/2014\/8778.4489","article-title":"Burden of antibiotic resistance in common infectious diseases: role of antibiotic combination therapy","author":"Mehta","year":"2014","journal-title":"J Clin Diagn Res"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0090","series-title":"WHO guidelines for Malaria 2022","author":"World Health Organisation","year":"2022"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0095","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1475-2875-9-136","article-title":"Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs","volume":"9","author":"Bousema","year":"2010","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12936-021-03821-z","article-title":"SERCAP: is the perfect the enemy of the good?","volume":"20","author":"White","year":"2021","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0105","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1021\/acsmedchemlett.2c00172","article-title":"Optimization of hERG and pharmacokinetic properties for basic Dihydro-8-H-purin-8-one inhibitors of DNA-PK","volume":"13","author":"Goldberg","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0110","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/acs.jmedchem.7b00969","article-title":"Relevance of half-life in drug design","volume":"61","author":"Smith","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030949","article-title":"P. falciparum in vitro killing rates allow to discriminate between different antimalarial mode-of-action","volume":"7","author":"Sanz","year":"2012","journal-title":"PLoS One"},{"issue":"298","key":"10.1016\/bs.pmch.2024.08.001_bb0120","first-page":"210","article-title":"Chloroquine resistance in Plasmodium falciparum Malaria parasites conferred by pfcrt mutations","volume":"2002","author":"Sidhu","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0125","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.pt.2012.08.002","article-title":"PfCRT and its role in antimalarial drug resistance","volume":"28","author":"Ecker","year":"2012","journal-title":"Trends Parasitol"},{"issue":"325","key":"10.1016\/bs.pmch.2024.08.001_bb0130","first-page":"1680","article-title":"Chloroquine transport via the malaria parasite's chloroquine resistance transporter","volume":"2009","author":"Martin","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0135","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2017.06.030","article-title":"Functional profiling of a plasmodium genome reveals an abundance of essential genes","volume":"170","author":"Bushell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0140","first-page":"360","article-title":"Uncovering the essential genes of the human malaria parasite Plasmodium falciparum by saturation mutagenesis","volume":"2018","author":"Zhang","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0145","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.pt.2021.01.009","article-title":"MalDA, accelerating Malaria drug discovery","volume":"37","author":"Yang","year":"2021","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0150","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1021\/acsinfecdis.1c00322","article-title":"Prioritization of molecular targets for antimalarial drug discovery","volume":"7","author":"Forte","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0155","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1021\/acs.jmedchem.8b00329","article-title":"Plasmodial kinase inhibitors: license to cure?","volume":"61","author":"Cabrera","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002252","article-title":"A murine model of falciparum-malaria by in vivo selection of competent strains in non-myelodepleted mice engrafted with human erythrocytes","volume":"3","author":"Angulo-Barturen","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0165","doi-asserted-by":"crossref","first-page":"13013","DOI":"10.1021\/acs.jmedchem.0c01411","article-title":"Identification of 2,4-disubstituted imidazopyridines as hemozoin formation inhibitors with fast-killing kinetics and in vivo efficacy in the plasmodium falciparum NSG mouse model","volume":"63","author":"Horatscheck","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6013","article-title":"The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance","volume":"13","author":"Murithi","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0175","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.chembiol.2020.04.001","article-title":"Inhibition of resistance-refractory P. Falciparum kinase PKG delivers prophylactic, blood stage, and transmission-blocking Antiplasmodial activity","volume":"27","author":"Vanaerschot","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0180","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1038\/s41467-023-40974-8","article-title":"Propensity of selecting mutant parasites for the antimalarial drug cabamiquine","volume":"14","author":"Stadler","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0185","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01345-22","article-title":"Integrating pharmacokinetic-pharmacodynamic modeling and physiologically based pharmacokinetic modeling to optimize human dose predictions for Plasmodium falciparum Malaria: a chloroquine case study","volume":"67","author":"Redhi","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0190","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1021\/acscentsci.6b00086","article-title":"Open source drug discovery: highly potent antimalarial compounds derived from the Tres Cantos Arylpyrroles","volume":"2","author":"Williamson","year":"2016","journal-title":"ACS Cent Sci"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0195","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0200","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1038\/s41467-022-33403-9","article-title":"A G358S mutation in the Plasmodium falciparum Na(+) pump PfATP4 confers clinically-relevant resistance to cipargamin","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0205","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41573-023-00772-9","article-title":"Antimalarial drug discovery: progress and approaches","volume":"22","author":"Siqueira-Neto","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0210","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ijpddr.2015.07.001","article-title":"The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs","volume":"5","author":"Spillman","year":"2015","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0215","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.chom.2012.12.006","article-title":"Na+ regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials","volume":"13","author":"Spillman","year":"2013","journal-title":"Cell Host Microbe"},{"issue":"329","key":"10.1016\/bs.pmch.2024.08.001_bb0220","first-page":"1175","article-title":"Spiroindolones, a potent compound class for the treatment of Malaria","volume":"2010","author":"Rottmann","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0225","first-page":"6","article-title":"Comparative chemical genomics reveal that the spiroindolone antimalarial KAE609 (Cipargamin) is a P-type ATPase inhibitor","author":"Goldgof","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0230","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1021\/cb500616x","article-title":"Mutations in the P-type cation-transporter ATPase 4, PfATP4, mediate resistance to both aminopyrazole and spiroindolone antimalarials","volume":"10","author":"Flannery","year":"2015","journal-title":"ACS Chem Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0235","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1021\/jm100410f","article-title":"Spirotetrahydro \u03b2-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria","volume":"53","author":"Yeung","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0240","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1128\/AAC.03393-14","article-title":"A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial spiroindolone KAE609 (cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers","volume":"58","author":"Leong","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0245","first-page":"65","article-title":"Defining the antimalarial activity of Cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum","author":"McCarthy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0250","first-page":"20","article-title":"Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa","author":"Ndayisaba","year":"2021","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0255","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/ciab716","article-title":"Efficacy of Cipargamin (KAE609) in a randomized, phase II dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum Malaria","volume":"74","author":"Schmitt","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0260","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1038\/s41467-022-33403-9","article-title":"A G358S mutation in the Plasmodium falciparum Na+ pump PfATP4 confers clinically-relevant resistance to cipargamin","volume":"13","author":"Qiu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0265","first-page":"14","article-title":"Generation of a mutator parasite to drive resistome discovery in Plasmodium falciparum","author":"K\u00fcmpornsin","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0270","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1128\/AAC.03942-14","article-title":"Lead clinical and preclinical antimalarial drugs can significantly reduce sporozoite transmission to vertebrate populations","volume":"59","author":"Upton","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0275","first-page":"7","article-title":"Modelling mosquito infection at natural parasite densities identifies drugs targeting EF2, PI4K or ATP4 as key candidates for interrupting malaria transmission","author":"Dechering","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0280","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nature09099","article-title":"Chemical genetics of Plasmodium falciparum","volume":"465","author":"Guiguemde","year":"2010","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0285","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1021\/acs.jmedchem.6b00752","article-title":"Hit-to-lead studies for the antimalarial Tetrahydroisoquinolone Carboxanilides","volume":"59","author":"Floyd","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0290","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12936-021-03617-1","article-title":"Selecting an anti-malarial clinical candidate from two potent dihydroisoquinolones","volume":"20","author":"Chen","year":"2021","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0295","doi-asserted-by":"crossref","first-page":"E5455","DOI":"10.1073\/pnas.1414221111","article-title":"(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of plasmodium","volume":"111","author":"Jim\u00e9nez-D\u00edaz","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0300","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(19)30611-5","article-title":"Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a\/b trial","volume":"20","author":"Gaur","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104065","article-title":"Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: an innovative approach in antimalarial drug development","volume":"80","author":"Gaur","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0310","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1021\/acs.jmedchem.2c02092","article-title":"Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials targeting PfATP4","volume":"66","author":"Ashton","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0315","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/ncomms6521","article-title":"Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum","volume":"5","author":"Vaidya","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0320","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00607-22","article-title":"Spirofused tetrahydroisoquinoline-oxindole hybrids (Spiroquindolones) as potential multitarget antimalarial agents: preliminary hit optimization and efficacy evaluation in mice","volume":"66","author":"Efange","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0325","doi-asserted-by":"crossref","first-page":"10292","DOI":"10.1038\/s41598-019-46500-5","article-title":"A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4","volume":"9","author":"Gilson","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0330","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1039\/C5OB02517F","article-title":"Antimalarial activity of novel 4-cyano-3-methylisoquinoline inhibitors against Plasmodium falciparum: design, synthesis and biological evaluation","volume":"14","author":"Buskes","year":"2016","journal-title":"Org Biomol Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pt.2011.05.005","article-title":"Protein translation in plasmodium parasites","volume":"27","author":"Jackson","year":"2011","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0340","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.molmed.2019.05.011","article-title":"tRNA deregulation and its consequences in cancer","volume":"25","author":"Santos","year":"2019","journal-title":"Trends Mol Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0345","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev-micro-032421-121210","article-title":"Targeting aminoacyl tRNA synthetases for antimalarial drug development","volume":"77","author":"Xie","year":"2023","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0350","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.drudis.2018.01.050","article-title":"Drug targeting of one or more aminoacyl-tRNA synthetase in the malaria parasite Plasmodium falciparum","volume":"23","author":"Manickam","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0355","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12936-016-1247-0","article-title":"Recent advances in the biology and drug targeting of malaria parasite aminoacyl-tRNA synthetases","volume":"15","author":"Khan","year":"2016","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0360","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1128\/AAC.00394-06","article-title":"Tetracyclines specifically target the Apicoplast of the Malaria parasite Plasmodium falciparum","volume":"50","author":"Dahl","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0365","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s13059-014-0511-2","article-title":"A genomic and evolutionary approach reveals non-genetic drug resistance in malaria","volume":"15","author":"Herman","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0370","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1002\/cmdc.201200045","article-title":"Characterization of Plasmodium liver stage inhibition by Halofuginone","volume":"7","author":"Derbyshire","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0375","first-page":"183","article-title":"Studies in human malaria. XXV. Trial of febrifugine, an alkaloid obtained from Dichroa febrifuga lour., against the Chesson strain of Plasmodium vivax","volume":"9","author":"Coatney","year":"1950","journal-title":"J Natl Malar Soc"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0380","doi-asserted-by":"crossref","first-page":"288ra77","DOI":"10.1126\/scitranslmed.aaa3575","article-title":"The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs","volume":"7","author":"Herman","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0385","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.antiviral.2018.11.017","article-title":"A potent prolyl tRNA synthetase inhibitor antagonizes chikungunya and dengue viruses","volume":"161","author":"Hwang","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0390","article-title":"The prolyl-tRNA synthetase inhibitor Halofuginone inhibits SARS-CoV-2 infection","author":"Sandoval","year":"2021","journal-title":"BioRxiv"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0395","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/nchembio.790","article-title":"Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase","volume":"8","author":"Keller","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0400","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.str.2017.07.015","article-title":"Targeting prolyl-tRNA synthetase to accelerate drug discovery against Malaria, Leishmaniasis, toxoplasmosis, cryptosporidiosis, and coccidiosis","volume":"25","author":"Jain","year":"2017","journal-title":"Structure"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0405","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1021\/acsinfecdis.8b00363","article-title":"The adaptive proline response in P. falciparum is independent of PfeIK1 and eIF2\u03b1 signaling","volume":"5","author":"Fagbami","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0410","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1038\/s41467-022-32630-4","article-title":"Elucidating the path to plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance","volume":"13","author":"Tye","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0415","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1021\/acsinfecdis.6b00078","article-title":"Biochemical and structural characterization of selective allosteric inhibitors of the Plasmodium falciparum drug target, Prolyl-tRNA-synthetase","volume":"3","author":"Hewitt","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0420","doi-asserted-by":"crossref","first-page":"5521","DOI":"10.1038\/ncomms6521","article-title":"Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum","volume":"5","author":"Vaidya","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0425","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.bbrc.2017.05.064","article-title":"Discovery of a novel prolyl-tRNA synthetase inhibitor and elucidation of its binding mode to the ATP site in complex with l-proline","volume":"488","author":"Adachi","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0430","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1021\/acsinfecdis.1c00020","article-title":"Repositioning and characterization of 1-(Pyridin-4-yl)pyrrolidin-2-one derivatives as plasmodium cytoplasmic prolyl-tRNA synthetase inhibitors","volume":"7","author":"Okaniwa","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0435","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nature19804","article-title":"Diversity-oriented synthesis yields novel multistage antimalarial inhibitors","volume":"538","author":"Kato","year":"2016","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0440","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41467-020-20478-5","article-title":"Structural basis of malaria parasite phenylalanine tRNA-synthetase inhibition by bicyclic azetidines","volume":"12","author":"Sharma","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0445","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1021\/jacs.7b06994","article-title":"Synthesis of a bicyclic Azetidine with in vivo antimalarial activity enabled by stereospecific, directed C(sp3)\u2013H Arylation","volume":"139","author":"Maetani","year":"2017","journal-title":"J Am Chem Soc"},{"issue":"376","key":"10.1016\/bs.pmch.2024.08.001_bb0450","first-page":"1074","article-title":"Reaction hijacking of tyrosine tRNA synthetase as a new whole-of-life-cycle antimalarial strategy","volume":"2022","author":"Xie","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115681","article-title":"Discovery and optimization of pyrazolopyrimidine sulfamates as ATG7 inhibitors","volume":"28","author":"Huang","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0460","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10969-014-9182-1","article-title":"Structural basis of malaria parasite lysyl-tRNA synthetase inhibition by cladosporin","volume":"15","author":"Khan","year":"2014","journal-title":"J Struct Funct Genomics"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0465","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis","volume":"116","author":"Baraga\u00f1a","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0470","doi-asserted-by":"crossref","first-page":"eadc9249","DOI":"10.1126\/scitranslmed.adc9249","article-title":"Cytoplasmic isoleucyl tRNA synthetase as an attractive multistage antimalarial drug target","volume":"15","author":"Istvan","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0475","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1073\/pnas.1011560108","article-title":"Validation of isoleucine utilization targets in Plasmodium falciparum","volume":"108","author":"Istvan","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0480","doi-asserted-by":"crossref","first-page":"4886","DOI":"10.1128\/AAC.00820-16","article-title":"Antimalarial Benzoxaboroles target Plasmodium falciparum Leucyl-tRNA synthetase","volume":"60","author":"Sonoiki","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0485","doi-asserted-by":"crossref","first-page":"14574","DOI":"10.1038\/ncomms14574","article-title":"A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0490","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1021\/acs.jmedchem.5b00678","article-title":"Benzoxaborole antimalarial agents. Part 4. Discovery of potent 6-(2-(alkoxycarbonyl)pyrazinyl-5-oxy)-1,3-dihydro-1-hydroxy-2,1-benzoxaboroles","volume":"58","author":"Zhang","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0495","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1405994111","article-title":"Analogs of natural aminoacyl-tRNA synthetase inhibitors clear malaria in vivo","volume":"111","author":"Novoa","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0500","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/j.bmcl.2013.02.075","article-title":"Borrelidin analogues with antimalarial activity: design, synthesis and biological evaluation against Plasmodium falciparum parasites","volume":"23","author":"Sugawara","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0505","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1128\/AAC.02220-13","article-title":"Inhibition of protein synthesis and malaria parasite development by drug targeting of methionyl-tRNA synthetases","volume":"59","author":"Hussain","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0510","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1261\/rna.071720.119","article-title":"Aminoacyl-tRNA synthetases","volume":"26","author":"Rubio Gomez","year":"2020","journal-title":"RNA"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0515","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0520","doi-asserted-by":"crossref","first-page":"9672","DOI":"10.1021\/acs.jmedchem.6b00723","article-title":"Discovery of a Quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy","volume":"59","author":"Baraga\u00f1a","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0525","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S1473-3099(21)00252-8","volume":"21","author":"McCarthy","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1211613","article-title":"The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts","volume":"13","author":"Parkyn Schneider","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0535","doi-asserted-by":"crossref","first-page":"36338","DOI":"10.1074\/jbc.M113.503557","article-title":"Kinetic flux profiling elucidates two independent acetyl-coa biosynthetic pathways in plasmodium falciparum","volume":"288","author":"Cobbold","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0540","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1021\/acsinfecdis.1c00414","article-title":"Plasmodium falciparum acetyl-CoA Synthetase is essential for parasite Intraerythrocytic development and chromatin modification","volume":"7","author":"Prata","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0545","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.chembiol.2021.07.010","article-title":"Chemogenomics identifies acetyl-coenzyme A synthetase as a target for malaria treatment and prevention","volume":"29","author":"Summers","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0550","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1128\/AAC.49.2.632-637.2005","article-title":"Provitamin B5 (Pantothenol) inhibits growth of the intraerythrocytic malaria parasite","volume":"49","author":"Saliba","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0555","first-page":"7","article-title":"The antimalarial activity of the pantothenamide \u03b1-PanAm is via inhibition of pantothenate phosphorylation","author":"Chiu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0560","doi-asserted-by":"crossref","first-page":"9917","DOI":"10.1126\/scitranslmed.aas9917","article-title":"Antimalarial pantothenamide metabolites target acetyl\u2013coenzyme A biosynthesis in Plasmodium falciparum","volume":"11","author":"Schalkwijk","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0565","first-page":"8","article-title":"Pantothenamides are potent, on-target inhibitors of Plasmodium falciparum growth when serum pantetheinase is inactivated","author":"Spry","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0570","doi-asserted-by":"crossref","first-page":"48205","DOI":"10.1074\/jbc.M204560200","article-title":"The antibiotic activity of N-pentylpantothenamide results from its conversion to ethyldethia-coenzyme A, a coenzyme A antimetabolite","volume":"277","author":"Strauss","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0575","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1038\/s41467-022-29688-5","article-title":"Preclinical characterization and target validation of the antimalarial pantothenamide MMV693183","volume":"13","author":"de Vries","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0580","first-page":"362","article-title":"Open-source discovery of chemical leads for next-generation chemoprotective antimalarials","volume":"2018","author":"Antonova-Koch","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0585","first-page":"9","article-title":"Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage plasmodium falciparum","author":"Yeh","year":"2011","journal-title":"PLoS Biol"},{"issue":"285","key":"10.1016\/bs.pmch.2024.08.001_bb0590","first-page":"1573","article-title":"Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs","volume":"1999","author":"Jomaa","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0595","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/cid\/cix1122","article-title":"Efficacy and safety of fosmidomycin-piperaquine as nonartemisinin-based combination therapy for uncomplicated falciparum malaria: a single-arm, age de-escalation proof-of-concept study in Gabon","volume":"66","author":"Mombo-Ngoma","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0600","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1128\/EC.00160-14","article-title":"Isoprenoid biosynthesis in plasmodium falciparum","volume":"13","author":"Guggisberg","year":"2014","journal-title":"Eukaryot Cell"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0605","first-page":"5","article-title":"Single-target high-throughput transcription analyses reveal high levels of alternative splicing present in the FPPS\/GGPPS from Plasmodium falciparum","author":"Gabriel","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0610","first-page":"12","article-title":"Cloning and characterization of bifunctional enzyme farnesyl diphosphate\/geranylgeranyl diphosphate synthase from Plasmodium falciparum","author":"Jord\u00e3o","year":"2013","journal-title":"Malar J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0615","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm0002578","article-title":"Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy","volume":"44","author":"Martin","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0620","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1021\/jm030084x","article-title":"Effects of bisphosphonates on the growth of Entamoeba histolytica and plasmodium species in vitro and in vivo","volume":"47","author":"Ghosh","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0625","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1073\/pnas.1118215109","article-title":"Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity","volume":"109","author":"No","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0630","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1021\/ml4000436","article-title":"Chemo-immunotherapeutic antimalarials targeting isoprenoid biosynthesis","volume":"4","author":"Zhang","year":"2013","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0635","first-page":"8","article-title":"The open access malaria box: a drug discovery catalyst for neglected diseases","author":"Spangenberg","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0640","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.chembiol.2017.11.010","article-title":"Specific inhibition of the bifunctional farnesyl\/geranylgeranyl diphosphate synthase in Malaria parasites via a new small-molecule binding site","volume":"25","author":"Gisselberg","year":"2018","journal-title":"Cell Chem Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0645","first-page":"41","article-title":"Nonbisphosphonate inhibitors of Plasmodium falciparum FPPS\/GGPPS","author":"Kabeche","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0650","first-page":"14","article-title":"Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma","author":"Jiang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0655","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/pcmr.12007","article-title":"Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies","volume":"25","author":"Bagrodia","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0660","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: an evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0665","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.1007\/s13277-016-5059-1","article-title":"Mechanisms of tumor cell resistance to the current targeted-therapy agents","volume":"37","author":"Khamisipour","year":"2016","journal-title":"Tumor Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0670","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.4155\/fmc.12.183","article-title":"Plasmodium kinases as targets for new-generation antimalarials","volume":"4","author":"Lucet","year":"2012","journal-title":"Future Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0675","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.1021\/acs.jmedchem.8b00329","article-title":"Plasmodial kinase inhibitors: license to cure?","volume":"61","author":"Cabrera","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0680","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/acsinfecdis.0c00724","article-title":"Plasmodium kinases as potential drug targets for malaria: challenges and opportunities","volume":"7","author":"Arendse","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0685","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.pt.2023.06.001","article-title":"Developing kinase inhibitors for malaria: an opportunity or liability?","volume":"39","author":"Mogwera","year":"2023","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0690","series-title":"Annual reports in medicinal chemistry","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.armc.2019.04.001","article-title":"Medicinal chemistry progression of antimalarial hits from phenotypic whole cell screening of SoftFocus libraries","author":"Cheuka","year":"2019"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0695","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14728222.2023.2185511","article-title":"Parasite and host kinases as targets for antimalarials","volume":"27","author":"Ong","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0700","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.chom.2010.10.002","article-title":"Parasite protein kinases: at home and abroad","volume":"8","author":"Doerig","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0705","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.3390\/molecules25245949","article-title":"Plasmodial kinase inhibitors targeting Malaria: recent developments","volume":"25","author":"Musti\u00e8re","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0710","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1471-2164-5-79","article-title":"Protein kinases of the human malaria parasite Plasmodium falciparum: the kinome of a divergent eukaryote","volume":"5","author":"Ward","year":"2004","journal-title":"BMC Genomics"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0715","series-title":"Advances in protein chemistry and structural biology","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/bs.apcsb.2020.10.004","article-title":"Targeting malaria protein kinases","author":"Cassiano","year":"2021"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0720","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.3390\/molecules25215182","article-title":"An update on development of small-molecule Plasmodial kinase inhibitors","volume":"25","author":"Moolman","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0725","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.pt.2021.01.002","article-title":"Parasite and host erythrocyte Kinomics of plasmodium infection","volume":"37","author":"Adderley","year":"2021","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0730","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1042\/BCJ20220217","article-title":"How many kinases are druggable? A review of our current understanding","volume":"480","author":"Anderson","year":"2023","journal-title":"Biochem J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0735","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1038\/ncomms8285","article-title":"Phosphoproteomics reveals malaria parasite protein kinase G as a signalling hub regulating egress and invasion","volume":"6","author":"Alam","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0740","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/mmi.13466","article-title":"Invasion of hepatocytes by Plasmodium sporozoites requires cGMP-dependent protein kinase and calcium dependent protein kinase 4","volume":"102","author":"Govindasamy","year":"2016","journal-title":"Mol Microbiol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0745","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/EC.00186-09","article-title":"The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage Schizogony","volume":"9","author":"Taylor","year":"2010","journal-title":"Eukaryot Cell"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0750","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003344","article-title":"Malaria parasite cGMP-dependent protein kinase regulates blood stage Merozoite secretory organelle discharge and egress","volume":"9","author":"Collins","year":"2013","journal-title":"PLoS Pathog"},{"issue":"328","key":"10.1016\/bs.pmch.2024.08.001_bb0755","first-page":"910","article-title":"A plant-like kinase in Plasmodium falciparum regulates parasite egress from erythrocytes","volume":"2010","author":"Dvorin","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0760","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.molbiopara.2006.05.003","article-title":"Anticoccidial kinase inhibitors: identification of protein kinase targets secondary to cGMP-dependent protein kinase","volume":"149","author":"Donald","year":"2006","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0765","doi-asserted-by":"crossref","first-page":"15913","DOI":"10.1074\/jbc.M108393200","article-title":"Purification and molecular characterization of cGMP-dependent protein kinase from apicomplexan parasites","volume":"277","author":"Gurnett","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0770","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/bioinformatics\/btp650","article-title":"Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis","volume":"26","author":"Huang","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0775","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41467-017-00572-x","article-title":"A potent series targeting the malarial cGMP-dependent protein kinase clears infection and blocks transmission","volume":"8","author":"Baker","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0780","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jcb.23034","article-title":"Two nucleus-localized CDK-like kinases with crucial roles for malaria parasite erythrocytic replication are involved in phosphorylation of splicing factor","volume":"112","author":"Agarwal","year":"2011","journal-title":"J Cell Biochem"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0785","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/1471-2148-11-321","article-title":"Structural and evolutionary divergence of eukaryotic protein kinases in Apicomplexa","volume":"11","author":"Talevich","year":"2011","journal-title":"BMC Evol Biol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0790","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/ncomms1558","article-title":"Global kinomic and phospho-proteomic analyses of the human malaria parasite Plasmodium falciparum","volume":"2","author":"Solyakov","year":"2011","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0795","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cell.2017.06.030","article-title":"Functional profiling of a plasmodium genome reveals an abundance of essential genes","volume":"170","author":"Bushell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0800","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.chom.2010.09.006","article-title":"The systematic functional analysis of plasmodium protein kinases identifies essential regulators of mosquito transmission","volume":"8","author":"Tewari","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0805","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3231","article-title":"Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase","volume":"14","author":"Swale","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0810","first-page":"365","article-title":"Validation of the protein kinase Pf CLK3 as a multistage cross-species malarial drug target","volume":"2019","author":"Alam","year":"1979","journal-title":"Science"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0815","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1021\/acsinfecdis.0c00566","article-title":"Structural basis for inhibitor potency and selectivity of plasmodium falciparum phosphatidylinositol 4-kinase inhibitors","volume":"6","author":"Fienberg","year":"2020","journal-title":"ACS Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0820","doi-asserted-by":"crossref","first-page":"E657","DOI":"10.1093\/cid\/ciaa368","article-title":"A phase 1, placebo-controlled, randomized, single ascending dose study and a volunteer infection study to characterize the safety, pharmacokinetics, and antimalarial activity of the plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048","volume":"71","author":"McCarthy","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0825","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01896-19","article-title":"Safety, tolerability, pharmacokinetics, and antimalarial activity of the novel plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048 in healthy volunteers","volume":"64","author":"Sinxadi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0830","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature12782","article-title":"Targeting Plasmodium PI(4)K to eliminate malaria","volume":"504","author":"McNamara","year":"2013","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0835","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/bdr2.2012","article-title":"Malarial PI4K inhibitor induced diaphragmatic hernias in rat: potential link with mammalian kinase inhibition","volume":"114","author":"Demarta-Gatsi","year":"2022","journal-title":"Birth Defects Res"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174300","article-title":"Research progress of phosphatidylinositol 4-kinase and its inhibitors in inflammatory diseases","volume":"907","author":"Li","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0845","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41467-020-20629-8","article-title":"Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV pandemic response box","volume":"12","author":"Reader","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0850","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1128\/AAC.01224-16","article-title":"Metabolomic profiling of the malaria box reveals antimalarial target pathways","volume":"60","author":"Allman","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0855","first-page":"14","article-title":"The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple Plasmodium kinases and life cycle stages","author":"Arendse","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0860","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis","volume":"546","author":"Manjunatha","year":"2017","journal-title":"Nature"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0865","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/14728222.2023.2185511","article-title":"Parasite and host kinases as targets for antimalarials","volume":"27","author":"Ong","year":"2023","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0870","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.micinf.2012.04.007","article-title":"The kinomes of apicomplexan parasites","volume":"14","author":"Miranda-Saavedra","year":"2012","journal-title":"Microbes Infect"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0875","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ijpara.2014.01.003","article-title":"An exported kinase (FIKK4.2) that mediates virulence-associated changes in Plasmodium falciparum-infected red blood cells","volume":"44","author":"Kats","year":"2014","journal-title":"Int J Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0880","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011747","article-title":"Plasmodium falciparum FIKK kinase members target distinct components of the erythrocyte membrane","volume":"5","author":"Nunes","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0885","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/s41564-020-0702-4","article-title":"An exported kinase family mediates species-specific erythrocyte remodelling and virulence in human malaria","volume":"5","author":"Davies","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0890","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1016\/j.csbj.2022.07.003","article-title":"Update and elucidation of plasmodium kinomes: prioritization of kinases as potential drug targets for malaria","volume":"20","author":"Borba","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0895","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1038\/s41591-022-01885-1","article-title":"Fostering drug discovery and development in Africa","volume":"28","author":"Winks","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0900","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1038\/s41467-023-41512-2","article-title":"First fully-automated AI\/ML virtual screening cascade implemented at a drug discovery Centre in Africa","volume":"14","author":"Turon","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0905","doi-asserted-by":"crossref","first-page":"43813","DOI":"10.1021\/acsomega.3c05664","article-title":"Machine learning approaches identify chemical features for stage-specific antimalarial compounds","volume":"8","author":"van Heerden","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0910","first-page":"6","article-title":"Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis","author":"Djaout","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0915","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010645","article-title":"Drug discovery research in Ghana, challenges, current efforts, and the way forward","volume":"16","author":"Amewu","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0920","first-page":"2","article-title":"Artificial intelligence for antiviral drug discovery in low resourced settings: a perspective","author":"Namba-Nzanguim","year":"2022","journal-title":"Front Drug Discov"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0925","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.pt.2022.06.005","article-title":"Keystone Malaria symposium 2022: a vibrant discussion of progress made and challenges ahead from drug discovery to treatment","volume":"38","author":"Kanai","year":"2022","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.pmch.2024.08.001_bb0930","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1021\/acsinfecdis.3c00041","article-title":"The 2022 H3D symposium: celebrating over a decade of African-led infectious disease drug discovery to enhance Global Health","volume":"9","author":"Woodland","year":"2023","journal-title":"ACS Infect Dis"}],"container-title":["Progress in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646824000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0079646824000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T13:06:22Z","timestamp":1756127182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0079646824000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443297809"],"references-count":185,"URL":"https:\/\/doi.org\/10.1016\/bs.pmch.2024.08.001","relation":{},"ISSN":["0079-6468"],"issn-type":[{"value":"0079-6468","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}